PHARMACYTE BIOTECH, INC. — Cash Flow Charts
13 quarters of history · ending 2026-01-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Capital Allocation Waterfall
Buybacks vs Stock-Based Comp
Net Debt Issuance
Cash Flow
Cash Flow by Activity
Operating Cash Flow↓-434.2% -$2M
$-2M
Free Cash Flow↓-434.2% -$2M
$-2M
Investing Cash Flow
$5M
Financing Cash Flow
$544K
Stock Buybacks↑+134.1% +$230K
$402K
Stock-Based Comp↑+1106.5% +$708K
$772K
Debt Issued
$7M
Debt Repaid
—
D&A
—
SBC Allocated Expense↑+1106.5% +$708K
$772K